Cost-effectiveness of strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit

Infection Control and Hospital Epidemiology

Volumn 36, Issue 1, 2015, Pages 17-27

  Gidengil, Courtney A ^a,b   Gay, Charlene ^c   Huang, Susan S ^d   Platt, Richard ^c   Yokoe, Deborah ^e   Lee, Grace M ^b,c  

^a RAND CORPORATION   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORHEXIDINE GLUCONATE; ANTIINFECTIVE AGENT; CHLORHEXIDINE; TOPICAL ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; COST EFFECTIVENESS ANALYSIS; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OUTCOME ASSESSMENT; PREVALENCE; SENSITIVITY ANALYSIS; SIMULATION; ADULT; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS; HEALTH CARE POLICY; HEALTH SURVEY; HETEROZYGOTE; HOSPITAL COST; MARKOV CHAIN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PREVENTION AND CONTROL; PROCEDURES; STAPHYLOCOCCAL INFECTIONS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TRANSMISSION; UNITED STATES;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; CARRIER STATE; CHLORHEXIDINE; COST-BENEFIT ANALYSIS; HEALTH POLICY; HOSPITAL COSTS; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS; MARKOV CHAINS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, ECONOMIC; POPULATION SURVEILLANCE; STAPHYLOCOCCAL INFECTIONS; UNITED STATES;

EID: 84922772440     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1017/ice.2014.12     Document Type: Article

References (70)

1. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
2. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007;13:1840–1846.
3. Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003;36:281–285.
4. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003;36:53–59.
5. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592–598.
6. Cosgrove SE, Qi Y, Kaye KS,Harbarth S,KarchmerAW, CarmeliY. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26:166–174.
7. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005;52:113–122.
8. Reed SD, Friedman JY, Engemann JJ, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005;26:175–183.
9. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004;25:425–430.
10. Healthcare-Associated Infections - Healthy People. http://healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicId=17. Accessed January 24, 2012.
11. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008;359: 821–832.
12. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012;307:804–812.
13. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 2006;98: 774–782.
14. Weinstein M, Fineberg H. Clinical Decision Analysis. Philadelphia: W. B. Saunders Company, 1980.
15. Datta R, Huang SS. Risk of infection and death due to methicillinresistant Staphylococcus aureus in long-term carriers. Clin Infect Dis 2008;47:176–181.
16. Huang SS, Hinrichsen VL, Datta R, et al. Methicillin-resistant Staphylococcus aureus infection and hospitalization in high-risk patients in the year following detection. PLOS ONE 2011;6: e24340.
17. Analy$ource. 2011, First DataBank Inc., © (2011). Data accessed August 31, 2012.
18. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillinresistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763–1771.
19. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcareassociated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996–1011.
20. The direct medical costs of healthcare-associated infections in US hospitals and the benefits of prevention. Centers for Disease Control and Prevention. 2009. http://www.cdc.gov/hai/pdfs/hai/scott_costpaper.pdf.
21. Huskins WC, Huckabee CM, O'Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011;364:1407–1418.
22. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med 2011;364:1419–1430.
23. Fraser TG, Fatica C, Scarpelli M, et al. Decrease in Staphylococcus aureus colonization and hospital-acquired infection in a medical intensive care unit after institution of an active surveillance and decolonization program. Infect Control Hosp Epidemiol 2010;31:779–783.
24. Robotham JV, Graves N, Cookson BD, et al. Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation. BMJ 2011;343:d5694.
25. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013;368:2255–2265.
26. Lee BY, Singh A, Bartsch SM, et al. The potential regional impact of contact precaution use in nursing homes to control methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2013;34:151–160.
27. Lee BY, Wong KF, Bartsch SM, et al. The Regional Healthcare Ecosystem Analyst (RHEA): a simulation modeling tool to assist infectious disease control in a health system. JAMIA 2013;20: e139–46.
28. Dantes R, Mu Y, Belflower R, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013;173:1970–1978.
29. Epstein L, Kallen AJ, Bellflower R, et al. Risk factors for invasive methicillin-resistant Staphylococcus aureus infection after discharge from acute-care hospitals - United States, 2011-2013. Centers for Disease Control and Prevention, 63rd Epidemic Intelligence Service Conference, 2014. Atlanta, GA; 2014.
30. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: A cost-benefit analysis in an intensive care unit. JAMA 1999;282:1745–1751.
31. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and-resistant Staphylococcus aureus infections. Ann Pharmacother 2004;38:1377–1382.
32. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At Wh at costs? Infect Control Hosp Epidemiol 1999;20:408–411.
33. The cost of antibiotic resistance: Effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002;23:106–108.
34. Kaye KS, Anderson DJ, Sloane R, et al. The effect of surgical site infection on older operative patients. J AmGeriatr Soc 2009;57:46–54.
35. Lilly CM, Zuckerman IH, Badawi O, Riker RR. Benchmark data from more than 240,000 adults that reflect the current practice of critical care in the United States. Chest 2011;140:1232–1242.
36. Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005;33:1266–1271.
37. Paladino JA, Poretz D. Outpatient parenteral antimicrobial therapy today. Clin Infect Dis 2010;51(Suppl 2):S198–208.
38. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007;51:423–428.
39. Machlin S, Chowdhury S. Statistical Brief #318: Expenses and characteristics of physician visits in different ambulatory care settings, 2008. AHRQ/MEPS Statistical Briefs. March 2011. http://www.meps.ahrq.gov/mepsweb/data_files/publications/st318/stat318.shtml. Accessed June 9, 2011.
40. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002;23:429–435.
41. Huang SS, Yokoe DS, Hinrichsen VL, et al. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2006;43:971–978.
42. Ellingson K, Muder RR, Jain R, et al. Sustained reduction in the clinical incidence of methicillin-resistant Staphylococcus aureus colonization or infection associated with a multifaceted infection control intervention. Infect Control Hosp Epidemiol 2011;32:1–8.
43. Larson E, Bobo L, Bennett R, et al. Lack of care giver hand contamination with endemic bacterial pathogens in a nursing home. Am J Infect Control 1992;20:11–15.
44. Pettinger A, Nettleman MD. Epidemiology of isolation precautions. Infect Control Hosp Epidemiol 1991;12:303–307.
45. Ridenour G, Lampen R, Federspiel J, Kritchevsky S, Wong E, Climo M. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients. Infect Control Hosp Epidemiol 2007;28:1155–1161.
46. Jernigan JA, Titus MG, Groschel DH, Getchell-White S, Farr BM. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol 1996;143:496–504.
47. Afif W, Huor P, Brassard P, Loo VG. Compliance with methicillin-resistant Staphylococcus aureus precautions in a teaching hospital. Am J Infect Control 2002;30:430–433.
48. Dedrick RE, Sinkowitz-Cochran RL, Cunningham C, et al. Hand hygiene practices after brief encounters with patients: an important opportunity for prevention. Infect Control Hosp Epidemiol 2007;28:341–345.
49. Golan Y, Doron S, Griffith J, et al. The impact of gown-use requirement on hand hygiene compliance. Clin Infect Dis 2006;42:370–376.
50. Weber DJ, Sickbert-Bennett EE, Brown VM, et al. Compliance with isolation precautions at a university hospital. Infect Control Hosp Epidemiol 2007;28:358–361.
51. Kim PW, Roghmann MC, Perencevich EN, Harris AD. Rates of hand disinfection associated with glove use, patient isolation, and changes between exposure to various body sites. Am J Infect Control 2003;31:97–103.
52. Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillinresistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasiexperimental multicenter trial. Crit Care Med 2009;37:1858–1865.
53. Wendt C, Schinke S, Wurttemberger M, Oberdorfer K, Bock-Hensley O, von Baum H. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: A randomized, placebo-controlled, doubleblind clinical trial. Infect Control Hosp Epidemiol 2007;28:1036–1043.
54. Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol 2009;30:959–963.
55. Flayhart D, Hindler JF, Bruckner DA, et al. Multicenter evaluation of BBL CHROMagar MRSA medium for direct detection of methicillin-resistant Staphylococcus aureus from surveillance cultures of the anterior nares. J Clin Microbiol 2005;43:5536–5540.
56. Paule SM, Mehta M, Hacek DM, Gonzalzles TM, Robicsek A, Peterson LR. Chromogenic media vs real-time PCR for nasal surveillance of methicillin-resistant Staphylococcus aureus: impact on detection of MRSA-positive persons. Am J Clin Pathol 2009;131:532–539.
57. Huang SS, Rifas-Shiman SL, Warren DK, et al. Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. J Infect Dis 2007;195:330–338.
58. Ridenour GA, Wong ES, Call MA, Climo MW. Duration of colonization with methicillin-resistant Staphylococcus aureus among patients in the intensive care unit: implications for intervention. Infect Control Hosp Epidemiol 2006;27:271–278.
59. Warren DK, Guth RM, Coopersmith CM, Merz LR, Zack JE, Fraser VJ. Epidemiology of methicillin-resistant Staphylococcus aureus colonization in a surgical intensive care unit. Infect Control Hosp Epidemiol 2006;27:1032–1040.
60. Clancy M, Graepler A, Wilson M, Douglas I, Johnson J, Price CS. Active screening in high-risk units is an effective and costavoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospital. Infect Control Hosp Epidemiol 2006;27:1009–1017.
61. Patel M, Weinheimer JD, Waites KB, Baddley JW. Active surveillance to determine the impact of methicillin-resistant Staphylococcus aureus colonization on patients in intensive care units of a Veterans Affairs Medical Center. Infect Control Hosp Epidemiol 2008;29:503–509.
62. Robicsek A, Beaumont JL, Thomson RB, Jr., Govindarajan G, Peterson LR. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol 2009;30:623–632.
63. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008;148:409–418.
64. Fishbain JT, Lee JC, Nguyen HD, et al. Nosocomial transmission of methicillin-resistant Staphylococcus aureus: A blinded study to establish baseline acquisition rates. Infect Control Hosp Epidemiol 2003;24:415–421.
65. Muller A, Talon D, Potier A, Belle E, Cappelier G, Bertrand X. Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units. Crit Care 2005;9:R246–250.
66. Kim T, Oh PI, Simor AE. The economic impact of methicillinresistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001;22:99–104.
67. Muder RR, Wagener MM, Yu VL. Methicillin-resistant Staphylococcus aureus in nursing homes. Ann Intern Med 1992; 116:267.
68. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillinresistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol 2009;30:453–460.
69. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 2006;10:R97.
70. Ibelings MM, Bruining HA. Methicillin-resistant Staphylococcus aureus: acquisition and risk of death in patients in the intensive care unit. Eur J Surg 1998;164:411–418.